Pending Biosimilars
Executive Summary
Biosimilar applications using the 351(k) pathway under review at FDA. Updated upon new submissions.
The official 351(k) pathway for biosimilar products was created in the Biologics Price Competition and Innovation Act, a component of the health care reform law. Listed below are applications submitted under that pathway. Biosimilar sponsors also can submit their products using the 505(b)2 NDA or conventional BLA pathways; those applications are only listed in the User Fee Goal Dates
chart.
Click on any column header to sort. Use the search box to filter only approved agents.
Click here for a full-page view